Flow-chamber device (T-TAS) to diagnose patients suspected of platelet function defects
Anna Lecchi1, Silvia La Marca1, Lidia Padovan1
1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.
Insights
The T-TAS device effectively detects severe platelet function defects like δ-storage pool disease (δ-SPD). However, its agreement with lumi-aggregometry is limited for milder defects and antiplatelet therapy response assessment.
Area of Science:
- Hematology
- Clinical Diagnostics
- Point-of-Care Testing
Background:
- Platelet function defect diagnosis is challenging due to complex, non-standardized methods.
- Evaluating new diagnostic tools is crucial for accurate patient care.
Purpose of the Study:
- To compare a new point-of-care device (T-TAS) with established methods for diagnosing platelet function defects.
- To assess T-TAS performance in patients with suspected defects and those on antiplatelet therapy.
Main Methods:
- A study involving 96 patients with suspected platelet function defects and 26 on antiplatelet therapy.
- Comparison of T-TAS with lumi-aggregometry and specific platelet function tests.
Main Results:
- T-TAS showed good agreement with lumi-aggregometry for severe defects (δ-storage pool disease, 80% agreement).
- T-TAS demonstrated lower sensitivity for milder defects (primary secretion defects).
- Agreement between T-TAS and lumi-aggregometry was poor for identifying antiplatelet therapy responders (54% agreement).
Conclusions:
- The T-TAS device is suitable for detecting severe platelet function disorders, such as δ-SPD.
- T-TAS has limited utility in assessing antiplatelet therapy response compared to lumi-aggregometry.
- Discrepancies highlight the need for standardized tests and clinical trial data linking platelet function to therapeutic outcomes.
Background:
Patients suspected of platelet function defects represent a diagnostic challenge for the clinical laboratory, mainly due to the complexity and poor standardization of screening methods. We compared a new flow-based chip-equipped point-of-care (T-TAS) device with lumi-aggregometry and other specific tests.
Materials And Methods:
The study included 96 patients suspected of platelet function defects and 26 patients referred to hospital for an evaluation of residual platelet function while on antiplatelet therapy.
Results:
Forty-eight of 96 patients displayed abnormal platelet function by lumi-aggregometry, and 10 of them had defective granule content and were classified as δ-storage pool disease (δ-SPD). T-TAS compared favorably with lumi-aggregometry in detecting the most severe forms of platelet function defects (i.e., δ-SPD) [test agreement (lumi-light transmission aggregometry [lumi-LTA] vs T-TAS) for the δ-SPD subgroup was 80% and K CHOEN 0.695. T-TAS was less sensitive to milder platelet function defects (i.e., primary secretion defects [PSD]). Concerning patients on antiplatelets, test agreement (lumi-LTA vs T-TAS) in detecting patients who were responders to this therapy was 54%; K CHOEN 0.150.
Discussion:
The results indicate that T-TAS can detect the more severe forms of platelet function defects such as δ-SPD. There is limited agreement of T-TAS with lumi-aggregometry in identifying responders to antiplatelets. However, this poor agreement is commonly shared by lumi-aggregometry and other devices owing to the lack of test specificity and of prospective data from clinical trials linking platelet function with therapeutic efficacy.
